Finance and markets: business, quotes, gold, energy and releases.
Johnson & Johnson’s venture capital arm and SV Health Investors’ Dementia Discovery Fund led a $100 million Series C round for Delix Therapeutics, which is developing versions of psychedelic compounds designed to avoid hallucinatory effects.
Delix said the financing will support development of Zalsupindole through a Phase IIb proof-of-concept study in recurrent major depressive disorder. It will also fund the company’s broader neuroplastogen pipeline.
The company expects to start a Phase II trial in the first half of 2027.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!